index.php?vrs=hemarina_francais
Send this article to a friend Print the page 

viadeo-hemarina facebook-hemarina flux rss hemarina linked in hemarina

News

Home > News & Media > News

 

Press Release


Brest University Hospital and HEMARINA announce positive Top-line results from first clinical trial of HEMO2life® in kidney preservation before human transplantation.

  • OxyOp trial represents the first use in human of the marine oxygen carrier HEMO2life®. HEMO2life® was added in preservation solution in order to reduce ischemia reperfusion injuries due to hypoxia during the preservation of the graft.
  • 3 month analysis of the multicenter study OxyOp* started in October 2015 shows an excellent safety profile for HEMO2life® and promising preliminary efficacy data in regard to existing standard of care in kidney transplantation.
  • HEMO2life® confirms its potential as a breakthrough oxygen-carrier innovation used as a universal additive to existing organ preservation solutions in static or dynamic (perfusion machine) environment.

Morlaix, Brest (France), Tuesday, November 14, 2017: Brest University Hospital and Hemarina announced today that the first ever clinical study (OxyOp) with an oxygen carrier (HEMO2life®) in human transplantation met its primary endpoint of demonstrating safety of HEMO2life® used as additive to existing hypothermic organ preservation methods.

Three months after the transplantation, preliminary data analysed over 60 patients in six French reference transplant centers showed the following Top line results:

  • No graft loss related to product, according to IDSMB, Independent Data Safety Monitoring Board
  • No death at 3 months
  • No major adverse event related to HEMO2life®
  • No immunological, allergic or pro-thrombotic effects
  • Promising preliminary efficacy data

Organ transplantation remains the last resort for a certain number of otherwise incurable medical conditions. Despite recent improvement in the field, organ preservation and ischemia-reperfusion injuries (IRI) associated with it remain an essential factor responsible for primary and long-term dysfunction after transplantation” said Prof. Benoit Barrou, Head of the Kidney Transplantation Program, Department of Urology, Nephrology and Renal Transplantation, Groupe Hospitalier Pitié Salpêtrière, Paris, France. “New interventions should be developed to enhance the quality of grafts at the end of preservation not only to reduce the consequence of IRI but also to expand the number of available transplantable grafts, thus reducing the worldwide organ shortage.”

Based on the results of the OxyOp study, the company intends to apply for a CE marking of HEMO2life® as additive to existing preservation solutions (before solid organ transplantation), in order to make this innovation available to patients and clinicians.

We are delighted with the 3 months results seen in OxyOp study, the first clinical trial with HEMO2life®. Data issued from 60 patients receiving a kidney preserved with the addition of HEMO2life® show an excellent safety profile for HEMO2life® in regard to both grafts and patients.  We continue of course to follow our patients to ensure that the results observed today will translate into significant benefits in the long term.” said Professor Yannick Le Meur, head of Nephrology and Kidney Transplantation Department at Brest University Hospital and investigator coordinator of the study.

“We want to thank the patients, family members and clinicians who participated in the OxyOp trial. This landmark study confirms the promising results seen in many preclinical studies so far and represents the first step of a new era in organ preservation. We are working intensively to make this product commercially available and to provide an effective tool to fight against the organ shortage and better meet the need of the patients registered on the waiting lists. Hemarina remains committed to its credo: to save lives by bringing its technology to patients worldwide” said Dr. Franck Zal, co-founder and CEO, Hemarina. “We look forward to further analysing the detailed results from OxyOp study and submitting them for presentation to a major medical meeting.”

*OxyOp : Evaluation of a marine OXYgen carrier, HEMO2life®, for hypOthermic kidney graft Preservation before transplantation


About OxyOp trial (NCT02652520)  

The multicenter clinical study OxyOp was designed to evaluate the safety and get preliminary efficacy data on HEMO2life® used as an additive in graft preservation solution. The study was financed by a public-private partnership: a national French grant (Programme hospitalier de recherche clinique PHRC) involving public funds and Hemarina’s private funds.  60 patients were transplanted in six French reference transplant centers with kidneys preserved in hypothermic conditions (static and perfusion machine) with supplementation with HEMO2life®. The primary objective of the trial was the safety of using HEMO2life® as an additive to current preservation solutions. Secondary endpoints were parameters of renal function, biomarkers and histological patterns of the transplanted organs. For more information on the OxyOp trial, go to www.clinicaltrials.gov.

About kidney transplant 

Kidney transplantation is the elective treatment for End Stage Renal Disease. It allows patients, whose kidneys have been altered by the disease, to prolong life expectancy and to enjoy a near normal quality of life. The average running time of a transplant is about thirteen years. During the year 2016, 3615 patients received a kidney transplant in France, but in the same time 5181 patients were registered on the waiting list. The vast majority of grafts are retrieved from brain-death donors and in recent years the profile of donors has changed including older donors with more comorbidities. Thus, the transplantation community is now facing a double challenge: firstly to enable the largest number of patients to receive a transplant, and secondly to increase the viability of grafts while they are more sensitive to IRI [Source: 2016 Report of the French Biomedicine Agency].


About Hemarina

Hemarina is a biotechnology company founded  in 2007 and headquartered in Morlaix, Finistère, France. The company specializes in the development of universal marine oxygen carriers. Hemarina has a technical & commercial affiliate in Boston (Hemarina Inc.) and a production site located on the island of Noirmoutier (France) so as offices in Paris.   

Hemarina identified four applications which are highly creative for short-medium term value including three medical applications and one industrial application:

       - A therapeutic oxygen carrier: HEMOXYCarrier®
       - An additive to organ preservation solutions: HEMO2life®
       - An oxygenating dressing: HEMHealing®

       - An input for industrial bioproduction: HEMOXCell® / HEMBoost®

For more information, visit our website: www.hemarina.com

Contacts:

Address:                Aéropole centre, 29600 Morlaix, France
Phone:                   +33 (0)2 98 88 88 23
E-mail:                    info@hemarina.com
Website:                 www.hemarina.com
Twitter:                   @HEMARINA
Facebook :            www.facebook.com/HemarinaBiotech 

About Brest University Hospital

Research is one of the three missions of Brest University Hospital, inseparable from care and education. Its aims are the acquisition of new knowledge and also, with regard to translational research, to facilitate patient access to the most innovative treatments and contribute to improving their care. This research is based on certified research units, which are a very important clinical research activity driven by clinical activity and medical technology poles. They have been supported since 2011 by the Multidisciplinary Research Institute. The CHRU research activity has grown steadily with a current portfolio of 764 studies including 78 interventional trials which were undertaken under its supervision.

Contacts:

Address:                2, avenue Foch, 29609 Brest cedex, France
Phone:                   +33 (0)2 98 22 39 79
E-mail:                    sec-drci@chu-brest.fr
Website:                 www.chu-brest.fr

HEMARINA has just achieved ISO 13485 : 2012 certification 

The Breton Marine Biotechnology Company Centered on the Development of Innovative Oxygen Carriers Announces a Fundraising of More than 8M€

 

Press Release


The Breton Marine Biotechnology Company Centered on the Development of Innovative Oxygen Carriers Announces a Fundraising of More than 8M€

Morlaix (France), March 9, 2017 - Hemarina, the marine biotechnology company that develops universal oxygen carriers for unsatisfied medical needs in the field of pathologies associated to anemia and ischemia of tissues, organs and body as a whole so as applications in the sector of industrial bioproduction, announces the great success of its last fundraising for a total amount exceeding  €8M.


For Dr Franck Zal, co-founder and Chief Executive Officer of Hemarina, “ the success of such a fundraising is an evidence of trust from our historical investors as Finistère Angels, Armor Angels, XMP/Business Angels des Grandes Ecoles and CM-CIC in patented disruptive technologies that we develop and in our business model. We also welcome with a great pleasure new French and European shareholders, mainly healthcare professionals, business executives, several Family offices and Force 29, the Caisse Régionale du Crédit Agricole du Finistère Investment Fund.

This new capital increase reinforces significantly our financial position. It will enable us to accelerate our research programs including regulatory preclinic and Phase I HEMOXYCarrier® study targeting ischemic pathologies and to realize a new large scale clinical trial on HEMO2life® product used in supplementation of transplant organ preservation solutions.

This study will be realized on the basis of very promising safety results of OxyOp multicenter clinical study. It will enable us to negociate licensing agreements on our proprietary technologies with serenity and strengthen our management team.”

“ Since 2008, we saw a real scientific and economic potential in Hemarina. Once again, being part of Hemarina story written by Franck Zal and his team just seemed obvious to us ” jointly declared Christophe Bapst et Michel Brandelet, respectively Presidents of Finistère Angels (http://finistereangels.fr) and Armor Angels (http://www.armorangels.org).

“ We are very happy to continue our contribution to the development of the wide-ranging public health project led by Hemarina ” stated Christian Dailly, instructor and coach for Business Angels des Grandes Ecoles (http://www.business-angels.info).

As a new institutional investor, Force 29 (http://force-29.bzh/), the Caisse Régionale du Crédit Agricole du Finistère investment vehicle, in the person of Didier Hamon, Investment Officer, concluded : “ Hemarina is  fully in accordance with  the promising projects we want to support, I mean projects driven by local innovative, added value and job-creating SME with similar DNA to ours. ”

 

About Hemarina  

Hemarina is a biotechnology company created in 2007 which has its head office in Morlaix (Finistère). The company is centered on the development of universal marine oxygen carriers. Hemarina has a technical and trade subsidiary in Boston (Hemarina Inc), a production subsidiary of its row material in Noirmoutier Island (France) so as offices in Paris.  

Hemarina identified four very creative applications in short and medium term including three medical applications and an industrial application: 

-      An therapeutic oxygen carrier : HEMOXYCarrier®
-      An additive for organ preservation solutions : HEMO2life®
-      An oxygenating dressing : HEMHealing®
-      An input for the industrial bioproduction : HEMOXCell®/HEMBoost®

For more information, please visit our website www.hemarina.com

Contacts:

Adresse :              Aéropole centre, 29600 Morlaix, France ‎
Téléphone :           +33 (0)2 98 88 88 23
E-mail:                   info@hemarina.com
Website :               www.hemarina.com
Twitter :                 @HEMARINA
Facebook :            www.facebook.com/HemarinaBiotech

Legal advisor of the Company:

CPC & Associés,
Ms Fiorucci & Ms Belin
pfiorucci@cpcassocies.com
lbelin@cpcassocies.com
www.cpassocies.com

 

Business France Announces Créative Next U.S. Contest Winner

 

FOR IMMEDIATE RELEASE

 

Business France Announces Créative Next U.S. Contest Winner

Biotechnology company Hemarina will be featured in the international Créative France campaign

 

New York, NY, February 9, 2016 Business France, the French national agency supporting the international development of the French economy, today announced the United States winner of Créative Next, a social media contest that shines the spotlight on France’s most innovative entrepreneurs around the world. Hemarina, a biotechnology company that develops innovative universal oxygen carriers from marine environments that are used in healthcare applications, was selected from a diverse group of businesses registered / established in the U.S. that were founded by French entrepreneurs demonstrating unparalleled creativity and excellence in their work.

 

“Hemarina is a shining example of how a new generation is carrying the tradition of creative genius into the future both in France and abroad in the U.S.,” said Muriel Pénicaud, French Ambassador for International Investment and CEO of Business France. “We are pleased that Créative Next allows us to give Hemarina even greater visibility in the marketplace.”  

 

As the winners of the Créative Next contest, Hemarina joins the ranks of noteworthy French companies and individuals like 42, a private computer-training school established by Xavier Niel that just opened an outpost in Silicon Valley, and Cédric Villani, winner of the Fields Medal - the highest honor in the field of mathematics, in being featured by Créative France, an international campaign that highlights France’s position at the forefront of business and innovation across industries, including technology, design, education, aviation and gastronomy.

 

The Créative Next contest kicked off in France in 2016 and has since been facilitated throughout nine countries across the globe, including India, Singapore and the United Kingdom. Each of the individual honorees showcases a new and exciting face of France with their disruptive innovations.  

 

“Hemarina is honored to be named the winner of Créative Next in the U.S. and is excited join French stars in their fields in promoting our native country’s biotechnology strengths,” said Dr. Franck Zal, CEO and Chief Scientific Officer of Hemarina. “We know that France is strong, ambitious and creative and look forward to sharing that message with the world.”

 

Hemarina develops marine universal oxygen carriers for healthcare applications—a decisive, patented breakthrough technology in regard to current and past developments of hemoglobin-based oxygen carriers (HBOCs). A clinical trial will soon be completed at kidney transplant centers located at six French university hospitals using HEMO2life®, an additive in graft preservation solution. In addition, HEMOXYCarrier® is a therapeutic oxygen carrier that aims to restore optimal oxygenation of an organism without the side effects noted with the first generation of HBOC (i.e. vasoconstrictive and hypertensive effects). This feature has been demonstrated in a pre-clinical study carried out by the Naval Medical Research Center and the results of this collaboration have been published. Finally, HEMHealing® is a wound dressing designed to deliver the quantity of oxygen needed for the healing of wounds that are chronic or treatment resistant by means of a natural gradient of oxygen pressure, generating major interest from key players worldwide.

 

The potential of such breakthrough innovation and the market addressed are impressive:  blood oxygen carrier market size was estimated to $72 billion in 2009 (Ernst & Young) in a worldwide blood shortage market of 100 million liters per year. Major HEMOXYCarrier® indications are emergency care related, including acute anemia or acute hemorrhage syndromes during post-injury phases. This innovation should allow rapid oxygenation recovery for patients.

 

Hemarina’s business model revolves around finding win-win partnerships with life sciences or pharmaceutical companies who wish to incorporate Hemarina’s technology in their medical devices or drug development process.

 

For additional information on Business France, please visit http://en.businessfrance.fr/ or https://twitter.com/businessfrance and for Créative France, visit http://creative.businessfrance.fr/ or https://twitter.com/creativefrance.

 

Business France

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program. Founded on Jan. 1, 2015, through a merger between UBIFRANCE and the Invest in France Agency, Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public- and private-sector partners. For more information, visit http://en.businessfrance.fr/.

 

Hemarina

Hemarina is a biotechnology company founded in 2007 and headquartered in Morlaix, Finistère, France. The company specializes in the development of universal marine oxygen carriers. Hemarina has an office in Paris, a technical & commercial affiliate in Boston (Hemarina Inc.) and a production site located on the island of Noirmoutier (France). 

Hemarina identified four applications which are highly creative for short-medium term value including three medical applications and one industrial application: 

        -A therapeutic oxygen carrier: HEMOXYCarrier®

        -An additive to organ preservation solutions: HEMO2life®

        -An oxygenating dressing: HEMHealing®

        -An input for industrial bioproduction: HEMOXCell® / HEMBoost® 

For more information, visit our website: www.hemarina.com

Kidney transplant: OxyOp multicenter clinical trial evaluating the use of the oxygen carrier HEMO2life® will continue in accordance with the protocol established


Kidney transplant: OxyOp multicenter clinical trial  evaluating the use of the oxygen carrier  HEMO2life®
will continue in accordance with the protocol established 
 


Morlaix, Brest (France), July 26th 2016 -

The multicenter clinical study OxyOp* (see October 22nd, 2015 press release) designed to evaluate the safety and get preliminary efficacy data on HEMO2life®, an oxygen carrier from marine annelid Arenicola marina, is allowed to continue.  HEMO2life® is used as an additive in graft preservation solution (1 gram per litre). Ten patients were included in the study which will enroll a total of sixty patients in six french reference transplant centers (Brest, Paris, Tours, Poitiers, Lyon &  Limoges).

In accordance with the current protocol and the « stop-and-go » rule, the Data Safety Monitoring Board made of independant experts and the scientific committee made of doctors designing the study, have just reported their conclusions after the information collected on the first 10 transplant patients was  followed-up and analysed. On the basis of these findings including patients’ safety, the Brest University Hospital allowed the clinical study to proceed.

 « Organs transplantation remains the only therapeutic option for most pathologies leading to an irreversible damage on vital organs function such as kidney. After collection and while waiting for the transplant, organs are stored in a cold place in preserving liquids. Today, such liquids made of water, various salts and colloids do not enable grafts optimal preservation and notably do not compensate for the oxygen deficiency (hypoxia) responsible for organ irreversible damage.  New technologies should be developed to enhance grafts preservation and face the deterioration of their substantive quality, thus also enabling to expand the number of available transplantable grafts. This is a huge challenge for all patients waiting for a transplant.  HEMO2life® fits perfectly with this approach » says Professor Yannick Le Meur, head of Nephrology and Kidney Transplantation Department at Brest University Hospital and investigator coordinator of the trial. 

« We sincerely thank healthcare professionals in all six investigation centers who invite us to share their excitement in the implementation of our breakthrough innovation. The use of HEMO2life® in hospital should greatly improve thousands of patients with renal impairment day-to-day lives » concludes Dr. Franck Zal, CEO of Hemarina.

*OxyOp : Evaluation of a marine OXYgen carrier, HEMO2life®, for hypOthermic kidney graft Preservation before transplantation

 

About kidney transplant

Kidney transplantation is the only treatment for End Stage Renal Disease. It allows patients, whose kidneys have been destroyed by the disease, to prolong life expectancy and to enjoy a near normal quality of life. The average running time of a transplant is about fifteen years. During the year 2014, 3232 patients received a kidney graft in France, but in the same time 4695 patients were registered on the waiting list. The vast majority of grafts are taken from donors with brain death and in recent years the profile of donors has changed and includes older donors with more cardiovascular history. Thus, transplantation is now facing a double challenge: firstly to enable the largest number of patients to receive a graft, while the number of donors is insufficient and secondly to increase the viability of grafts while they are more fragile and more susceptible to ischemic lesions [Source: 2014 Report of  the Biomedicine Agency on Medical and Scientific Graft Harvesting in France].


About Hemarina

Hemarina is a biotechnology company founded  in 2007 and headquartered in Morlaix, Finistère, France. The company specializes in the development of universal marine oxygen carriers. Hemarina has a technical & commercial affiliate in Boston (Hemarina Inc.) and a production site located on the island of Noirmoutier (France).

Hemarina identified four applications which are highly creative for short-medium term value including three medical applications and one industrial application:

        -A therapeutic oxygen carrier: HEMOXYCarrier®

        -An additive to organ preservation solutions: HEMO2life®

        -An oxygenating dressing: HEMHealing®

        -An input for industrial bioproduction: HEMOXCell® / HEMBoost®

For more information, visit our website: www.hemarina.com

Contacts:

Address:                Aéropole centre, 29600 Morlaix, France

Phone:                   +33 (0)2 98 88 14 02

E-mail:                    media@hemarina.com

Website:                 www.hemarina.com

Twitter:                   @HEMARINA

Facebook :            www.facebook.com/HemarinaBiotech


About Brest University Hospital

Research is one of the three missions of Brest University Hospital, inseparable from care and education. Its aims are the acquisition of new knowledge and also, with regard to translational research, to facilitate patient access to the most innovative treatments and contribute to improving their care. This research is based on certified research units, which are a very important clinical research activity driven by clinical activity and medical technology poles. They have been supported since 2011 by the Multidisciplinary Research Institute. The CHRU research activity has grown steadily with a current portfolio of 764 studies including 78 interventional trials which were undertaken under its supervision.

Contacts:

Address:                2, avenue Foch, 29609 Brest cedex, France

Phone:                   +33 (0)2 98 22 39 79

E-mail:                    sec-drci@chu-brest.fr

Website:                 www.chu-brest.fr

Hemarina was awarded first prize as SME of the Year. The FAB Award was handed over to Hemarina from the French American Chamber of Commerce, New England (FACCNE)

Press release

HEMOXCell®

 

For more information on HEMOXCell®, Cell growth activator, please refer to our brochure.

HEMARINA, ORPHY, the UBO laboratory, and the University Hospital (CHRU) of Brest launch HEMOXYCHOC, the preclinic project designed to assess the efficacy & safety of HEMOXYCarrier® in the management of uncontrolled hemorrhagic shock.


Morlaix, February 11th, 2014 -

Hemorrhagic shock is the second leading cause of injury death after brain injuries. Such traumas lead to a reduction of patient oxygenation resulting from a simultaneous loss of plasma and red blood cells. HEMARINA extracellular hemoglobin seems to be an excellent candidate for this kind of accident. Therefore, the purpose of this project is to evaluate the interest of using this molecule in case of hemorrhagic shock on a preclinical model.

 This project financed by the Brittany Regional Council is based on a teamwork between three complementary partners :

 1. The company HEMARINA (industrial partner) :

 HEMARINA is the single company worldwide to work on this type of molecule and willing to develop a therapeutic oxygen carrier. All HEMARINA technologies are patented breakthrough innovations (14 international patents).
Dr. Franck ZAL, HEMARINA’s co-founder, CEO and Chief Scientific is « extremely satisfied with this collaboration with ORPHY laboratory and the University Hospital (CHRU) of Brest ». He is very pleased with « both complementarity, scientific interconnection and close geographic location of the partners involved in this project ».

 2. ORPHY, UBO’s laboratory (public research partner) :

ORPHY is a research unit in physiology combining both fundamental and applied approaches. The purpose of its work is to study the effects of the HEMOXYCarrier® molecule on an animal model.
Mrs Christine Moisan, director of the ORPHY team (EA4324) is very satisfied with this collaborative momentum (industrialist, physiologists and clinicians) initiated around a project offering potential significant clinical benefit.

 3. ARSIBOU department (Anesthésie-Réanimations-SI-Blocs opératoires-Urgences) part of the CHRU of Brest (University Medical Centre partner) :

 This key partner will provide HEMOXYCarrier® final user feedback. The involvement of Brest CHRU hospital practitioners facing care and management of patients with hemorrhagic shock is a major asset that enables integrating HEMOXYCarrier® clinical use conditions to the ongoing project.

Prof. Yves OZIER, head of the ARSIBOU department, expects a considerable contribution from the development of « a tissue re-oxygenation solution which should reduce the damaging effects of the hemorrhagic shock in emergency medicine ». He is also pleased with a « collaborative teamwork in the field ».


About HEMARINA :

HEMARINA is a biotechnology start-up based in Morlaix (France), developing innovative solutions based on marine molecules for patients and healthcare industry : universal oxygen carriers’ portfolio and pipeline products. HEMARINA has four core business programs that all of them are patented breakthrough innovations : organs transplantation and tissues conservation, blood substitutes, infections and wound healing and bio-production. HEMARINA core assets and know-how are based on a world-renowned scientific expertise coupled with its unique positioning of innovative solutions provider meeting public health issues requirements.
For more information about HEMARINA, please visit www.hemarina.com. 

HEMARINA Contacts :
Address : Aéropole centre, 29600 Morlaix, France ‎
Phone : +33 (0)2 98 88 14 02
E-mail : media@HEMARINA.com
Website : www.hemarina.com
Twitter : @HEMARINA
Facebook : www.facebook.com/HemarinaBiotech 


About ORPHY :

ORPHY is a combined Research Unit made up of 17 teacher-researchers issued from 4 components of the university of Brest : Sciences, Medicine, Literature, Physical activity and sports science. ORPHY studies the physiological mechanisms involved in optimising collaboration between organisms and their physical environment. The aim of this work is 1) to develop diagnostic and therapeutic tools dedicated to medicine 2) to have access to environmental assessment evaluation tools (natural or human induced) affecting the relationship between organism and environment.

For more information about ORPHY, please contact Recherche@physiology-orphy.fr or visit www.physiology-orphy.fr

About Brest CHRU & ARSIBOU department :

Research is one of the three missions of the Brest CHRU, intimately linked to care and teaching activity. This work aims to facilitate the acquisition of new knowledge and as far as the translational research is concerned, to also allow easier access to most innovative treatments for patients in western Brittany, improving medical care. ARSIBOU is managed by Prof. Yves OZIER, formerly Chief of anaesthesia and ventilation at the Hôpital Cochin in Paris. 

Dr Franck Zal, CEO of HEMARINA, wins the prize « Biotech d’avenir » Technology Fast 50 Western France organised par Deloitte In Extenso

Morlaix, Finistère – 8/11//2013 – HEMARINA, French based biotechnology company, is pleased to announce its co-founder, CEO and Chief Scientific Officer, Dr. Franck Zal is awarded the prize "Biotech future "2013 (West Region of France) by Deloitte and In Extenso.


 

This is a new award coming forth the first time in the list of “Deloitte Technology Fast 50” Edition 2013, organized by Deloitte and In Extenso for the past 13th consecutive year. It aims to recognize the company in biotechnology sector, which has been operating in the past over 3 years and having managed running one of the largest fundraising capitals in its region during 2012.

 


"We award the winner of ‘Biotech Future’ 2013 West Region in France to HEMARINA because of its promising innovation and technology in the field of extracellular hemoglobin of marine origin, led by the head Dr. Franck Zal and his team, who are dedicated to explore the new path and huge potential to developing new medicament. What even more remarkable is HEMARINA has achieved three successful fundraising since 2009, which is a token of appreciation and trust from its financial partners. These involved a mix of economical performances by cautious investors with selective decisions to choose the company to invest." Says Thierry de Gennes, Partner in charge of “Deloitte Technology Fast 50” Western France.

 


"I am very delighted to receive this award from Deloitte and In Extenso. It is an upstream encouragement to our research subject for industrial applications. I’d like to thank Deloitte and In Extenso and also address my appreciations to all HEMARINA employees and shareholders who have supported us." Says Dr Franck Zal, CEO and Chief Scientific Officer of HEMARINA.

 


HEMARINA, a heart dedicated to life science since 2007

 

 

In 2007, Dr Franck Zal created HEMARINA to exploit the subject of his thesis, namely breathing marine worms colonizing the intertidal zone. “The basic research in past over 20 years in CNRS research group were very essential for me, with which I distinguished marine annelid hemoglobin and discovered a molecule with all the properties of a universal oxygen carrier. This innovative hemoglobin has very exceptional characteristic and it could meet the specifications of a universal blood substitute established by the medical community." Dr. Franck Zal also commented.

 


From the beginning, Dr. Franck Zal has been surrounded by best technical and financial experts and environments. In 2008, he raised the first funds from INSERM Transfer Initiatives and Finistère Angels. These investors joined the board with their expertise to help HEMARINA develop and continuously drive

growth of the Company.

 

 

Today HEMARINA is the only company in the world who is working on hemoglobin marine worms for therapeutic and industrial applications with 14 portfolios of international patents.

 


Keys to Success :

• Innovations of major disruptions

• Strong technical, financial and people skills

• A high value-added positioning in markets

• The vertical integration of the value chain

 


About HEMARINA:

HEMARINA is a biotechnology start-up based in Morlaix (France); developing innovative solutions based on marine molecules for patients and healthcare industry: universal oxygen carriers’ portfolio and pipeline products. HEMARINA has four core business programs that all of them are patented breakthrough innovations: organs transplantation and tissues conservation, blood substitutes, infections and wound healing and bio-production. HEMARINA core assets and know-how are based on a world-renowned scientific expertise coupled with its unique positioning of innovative solutions provider meeting public health issues requirements.

For more information about HEMARINA, please visit www.hemarina.com

HEMARINA Contacts:

Address:         Aéropole centre, 29600 Morlaix, France ‎

Phone:             +33 (0)2 98 88 14 02

E-mail:    media@HEMARINA.com

Website:          www.hemarina.com

Twitter:            @HEMARINA

Facebook:       www.facebook.com/HemarinaBiotech

HEMARINA & LFB Biomanufacturing announced the signature of an agreement for the manufacturing of HEMO2life®

Morlaix, Finistère - 17/09/2013 – HEMARINA, entreprise française de biotechnologies, est très heureuse
d'annoncer que son co-fondateur, directeur scientifique et PDG, le Dr Franck Zal, vient de se voir décerner
le prix « Born Global » 2013 (Région Ouest) par EY.
EY rend hommage à l’esprit d’entreprise de Dr Franck Zal, qui se traduit par un « esprit d’innovations », de
« solides compétences techniques, financières et humaines », « un positionnement sur des marchés
à forte valeur ajoutée » et « l’intégration verticale de sa chaîne de valeur ».
En 2007, Dr Franck Zal crée HEMARINA afin d’exploiter le sujet de sa thèse, à savoir la respiration des vers
marins colonisant la zone de balancement des marées. Dès le début, Dr Franck Zal a su s’entourer des
meilleurs experts techniques et financiers. En 2008, il lève les premiers fonds auprès d’INSERM Transfert
Initiatives et de Finistère Angels. Ces investisseurs sont venus compléter le réseau de compétences sur
lequel Dr Franck Zal peut s'appuyer et ainsi poursuivre la croissance de sa société.
Passées les difficultés des premières années et notamment la recherche de fonds en amorçage, Dr Franck
Zal peut à présent se consacrer au développement de HEMARINA qui repose sur des solutions
technologiques ayant trois applications thérapeutiques (une solution de préservation d’organes, le
transporteur universel d’oxygène thérapeutique et le pansement actif) et une application industrielle (le biobooster
pour la production de protéines recombinantes) en faisant le choix de l’intégration verticale de sa
chaîne de valeur. En 6 ans, Dr Zal est parvenu à donner une dimension internationale à sa société. A
présent, HEMARINA dispose d’une équipe de plus de 30 experts et compte deux bureaux basés en Europe
et aux États-Unis. Forte de son expérience et de ses compétences dans le domaine des sciences de la vie,
HEMARINA participe à sauver des vies.

Morlaix and Alès - September 26th, 2013 - HEMARINA and LFB Biomanufacturing announced the signature of an agreement for the manufacturing of HEMO2life®

HEMARINA, a French based marine biotechnology company dedicated to the R&D of universal oxygen carrier solutions, signed an industrial subcontracting agreement with LFB Biomanufacturing, LFB group's subsidiary specialized in the manufacturing of active protein solutions for pharmaceutical applications, leading up to the preparation of HEMO2life® regulatory batches.

The HEMO2life® is a major breakthrough innovation in the field of organ preservation solutions. This product developed by HEMARINA enables preservation of organs and tissues under optimal physiological conditions due to oxygen contribution essential to their survival. Indeed, once the organ is removed from the donor it will go through an ischaemia/reperfusion cycle that could induce lesions and graft failures after transplant. HEMO2life® can make up for these two major issues during transplant as an oxygen carrier is facing free radicals during reperfusion.

The pre-clinical results induced and published in the international journal American Journal of Transplantation (2011; 11: 1845–1860) showed the graft preservation with HEMO2life®, compared with clinical use solutions, induces fast resumption of normal function and extended preservation time on renal cellular model.

 It is a real satisfaction for LFB Biomanufacturing to offer its expertise and abilities enabling the preparation of this unique product dedicated to organs and tissues preservation,” says Roland Béliard, Chairman of LFB Biomanufacturing. The first batches of this extraction hemoglobin will be issued at the end of 2013 and the beginning of 2014 from Alès plant (Gard). This agreement is also a real opportunity for us to manufacture locally a therapeutic solution developed by an innovative French based biotechnology company.

We are very pleased with this agreement signed with LFB Biomanufacturing, subsidiary of the LFB group.This is a crucial step for HEMARINA, willing to capitalise on the outstanding outlets offered by HEMO2life® and to work with a major French biopharmaceutical group for this type of solution which significantly increases engraftment success. Organ is so valuable that a special attention must be given to its preservation conditions, not only for the patient but also for the donor family.” says Dr. Franck Zal, CEO and co-founder of HEMARINA.


About LFB Biomanufacturing

LFB Biomanufacturing is a company specialized in the development and the manufacturing of recombinant proteins through cell culture, with a specific know-how in the field of monoclonal antibodies. LFB Biomanufacturing can provide a full range of bioproduction services, including cell lines development, research and manufacturing of cell production and purification processes as well as manufacturing of clinical and commercial batches of active substances for biological.  (http://www.lfbbiomanufacturing.com)

LFB Biomanufacturing is an LFB group's subsidiary, the leading manufacturer of plasma-derived medicinal products in France, 5th worldwide and also among the leading European companies for the development of new-generation proteins and treatments based on biotechnologies. In 2012, the Group had 1,887 employees and generated a total turnover of € 466 million.
http://www.lfb.fr

Press contact : Sandrine Charrières, Corporate communications director
01 69 82 72 80,
charrieres@lfb.fr


About HEMARINA

HEMARINA is a biotechnology start-up based in Morlaix (Finistère, France), developing innovative solutions based on marine molecules for patients and healthcare industry. These universal oxygen carriers’ molecules are developed for various therapeutic and industrial applications. HEMARINA has four core research programs which all of them are patented breakthrough innovations : organs transplantation and tissues conservation, blood substitutes, infections and wound healing as well as bio-production. HEMARINA core assets and know-how are based on a world-renowned scientific expertise coupled with its unique positioning of innovative solutions provider meeting public health issues requirements.

Pour plus d’informations à propos de Hemarina, visitez www.hemarina.com

Contact :
Adresse:         Aéropole centre, 29600 Morlaix, France
Phone:            +33 298 881 402
E-mail
:             media@hemarina.com
Website :        www.hemarina.com
Twitter :          @HEMARINA
Facebook :     www.facebook.com/HemarinaBiotech

Dr. Franck ZAL, CEO of HEMARINA Received “Born Global” Prize, Western France, organized by EY & L’Express

MORLAIX, France - 2013/09/17 – HEMARINA, the French based biotechnology company, is honored to announce its Chief Executive Officer, Scientific Executive Officer and Co-Founder Dr. Franck Zal today received the Western France “Born Global” Prize 2013 from EY.

EY pays tribute to Dr. Franck Zal for his “innovations spirit”, “strong technical, financial and people skills”, “a high value-added positioning in the market” and “the vertical integration of the value chain”. In 2007, Dr. Franck Zal created HEMARINA to develop the work from his academic thesis on the respiration of marine worms colonizing the intertidal zone. From the beginning, Dr. Franck Zal has been surrounded by the best technical and financial experts. In 2008, he raised his first funds from INSERM Transfer Initiativesand Finistère Angels. These investors have given Dr. Franck Zal and the company a reliable financial support and resources to continue HEMARINA’s growth.

By having passed through difficult years in the beginning of HEMARINA’s establishment, especially on research funds to drive the company’s operation, Dr. Franck Zal is now able to fully focus on HEMARINA’s developments which include the technology dedicated to three major therapeutic applications (an Organ Preservations Solution, the Universal Oxygen Carrier and the Oxygenating Dressing), as well as an industrial application (bio-booster for the production of recombinant proteins). The outreach crosses a vertical integration of the value chain. Now Dr. Franck Zal has successfully led HEMARINA to transform the business model to international market together with more than 30 experts in 2 offices based in Europe and North America to help HEMARINA to deliver company’s vision of saving lives with their abilities and strengths in lifescience domain.

“I’m very happy to be recognized and receive this prize from EY today. For the past 6 years, thinking global and going beyond borders has always been the fundamental key to drive HEMARINA to deploy our strategy. It helped us to outreach our goal of saving more lives. HEMARINA has the ambition to become the worldwide cells, tissues, organs and full organisms oxygenation leader, for both human and animal, by using our unique breakthrough patented technologies,” said by Dr. Franck Zal, Chief Executive Officer and Scientific Executive Officer, HEMARINA.

"This annual event honors outstanding entrepreneurs, women and men who contribute to development and innovation,” said by Philippe Fourquet, EY Partner, Director of the Western Region and person in charge of the Entrepreneurs Market. This Award of Annual Entrepreneur takes places in seven major regions in France: East, Ile-de-France, Mediterranean, Northern France, Western France, Rhone-Alpes and Southwest. The regional winners will compete for the national award in each of their category.

Dr. Franck Zal, the 46-year-old passionate leader, after finishing his Ph.D. study of Biological Oceanography at Pierre and Marie Curie University (UMPC), spent three years abroad as part of his post-doctor program from 1996 to 1999, including two years in Santa Barbara University in California, USA and one year in Antwerp University. Dr. Franck Zal was then recruited by CNRS as a Research Fellow and received his habilitation research at UPMC in 2001. In 2003, he became head of the “Eco-physiological Team: Molecular Evolution and Adaptation" in Roscoff. He is currently having his MBA study at ESC Rennes School of Business.

Dr. Franck Zal is also highly active and involved in social activities within the Breton and national networks, as well as the President and the Founder of “Bretagne Biosciences” which provides a both national andinternational platform for communications and events.

 

About HEMARINA:

HEMARINA is a biotechnology start-up based in Morlaix (Finistère), France, developing innovative solutions based on marine molecules for patients and healthcare industry. These universal oxygen carriers molecules are developed for various therapeutic and industrial applications. HEMARINA has four core research programs which all of them are patented breakthrough innovations: organs transplantation and tissues conservation, blood substitutes, infections and wound healing and bio-production. HEMARINA core assets and know-how are based on a worldrenowned scientific expertise coupled with its unique positioning of innovative solutions provider meeting public health issues requirements.

For more information about HEMARINA, please visit www.hemarina.com

 

Contacts:

AddressAéropole centre, 29600 Morlaix, France
Phone+33 298 881 402
E-mail: media@HEMARINA.com
Twitter: @HEMARINA
Facebook: www.facebook.com/HEMARINABiotech

HEMARINA & EUROBIO have entered into a distribution agreement for HEMOXCell®

HEMARINA and EUROBIO have entered into a distribution agreement for HEMOXCell®

 

PARIS, France – May 21th , 2013 – HEMARINA and EUROBIO, announce the signature of a commercial distribution agreement for HEMARINA’s laboratory product for accelerating cell cultures HEMOXCell®.

 

This agreement allows HEMARINA to market its first product in Europe. HEMARINA strategy is to partner with leading distributors of laboratory reagent and products while maintaining its internal development focusing on human health applications. This approach yields HEMARINA a greater degree to active the commercialization process of HEMOXCell® patented ingredients and effectiveness on cellular models widely used in major target markets.

Under the agreement, EUROBIO will market HEMOXCell® to its extensive customer base of R&D private and academic research centers and units. Through its multiple business presence and distribution agreements, located in Europe, Middle East and North Africa, all set with a dedicated sales team, EUROBIO is adding a new product, which is also a unique one to its line for cell culture.

 

Doctor Franck Zal, Chief Executive Officer and Scientific Executive Officer, HEMARINA, commented “We are very excited about that agreement which opens us the doors to France and then the rest of Europe, Middle East and North Africa regions in the cellular field. Partnering with such an important distributor as EUROBIO is a key step for HEMARINA towards unleashing the commercial potential of HEMOXCell®”

 

“We are very pleased that HEMARINA put its trust in our company. HEMOXCell® represents a new market opportunity. Our marketing, sales and technical support capabilities combined with the uniqueness and performance of HEMOXCell® should translate into great commercial success”, added Denis Fortier, General Manager, EUROBIO.

 

HEMOXCell® is a biotechnology based product dedicated to researchers willing to improve quality and accelerate cell cultures. HEMOXCell® will be fully commercialized in France by the second quarter this year and will be available across Europe, Middle East and North Africa by 2014 and 2015.

 

About HEMARINA:

HEMARINA is a biotechnology start-up based in Morlaix, France; developing innovative solutions for patients and healthcare industry based on its universal oxygen carriers portfolio and pipeline products. HEMARINA has four core business programs that all of them are patented breakthrough innovations: organs transplantation and tissues conservation, blood substitutes, infections and wound healing, and bio-production. HEMARINA core assets and knowhow are based on marine molecules and its corporate culture, policy and social responsibility are based on high unmet medical needs focus, public health issues solving mindset, excellence in science and processes, nature conservation and environment friendly approaches and attitudes.

For more information about Hemarina, visit www.hemarina.com

 

About EUROBIO:

EUROBIO is a french company manufacturing solutions for research on immunology, molecular and cellular biology. Celebrating half a century of history, EUROBIO is committed to developing innovative products dedicated to satisfied needs of research and diagnostics laboratories. EUROBIO has developed its own production unit and has two operating divisions: Life Sciences and Diagnostics managed by high-performing staff, and has always been committed to deliver  high-quality products, services and support. EUROBIO is working closely with scientists in academic research institutes i (CNRS, INSERM, INRA,… ), alongside biotechnology and Pharma companies, universities, hospitals and medical laboratories.

For more information about EUROBIO, visit www.eurobio.fr

 

About HEMOXCell®:

Intended Use: HEMOXCell® is an Oxygen carrier used to facilitate and enhance the growth of cells and the expression of recombinant proteins in cell culture systems. / Features: Macromolecule of 3,6MDa extracted from marine invertebrate and provides superior growth of cells when added to cell culture medium compared to cell culture medium alone. / Format Features: HEMOXCell® is a ready to use solution to be added in cell culture medium. For more information or query about HEMOXCell®, please contact EUROBIO.

 

Contacts:

 

For HEMARINA:

Phone: +33 298 880 360

E-mail: media@hemarina.com

Website: www.hemarina.com

Twitter: @Hemarina

 

For EUROBIO AbCys:

Phone: +33 169 079 477

E-mail: adv@eurobio.fr

Website: www.eurobio.fr

HEMARINA expands its operations to Boston U.S.A. Hemarina Inc. will be the company affiliate for the America

HEMARINA, the French based Biotechnology Company, today announced its establishment in Boston, Massachusetts USA thru the incorporation of Hemarina Inc. on March 15th, 2013. The new affiliate will be in charge of North and South America and will allow HEMARINA to deploy its global strategy more efficiently, and will be the corporate link between its headquarters located in Morlaix, France to facilitate its partnerships in the Americas. Seven years after its creation, HEMARINA has decided to accelerate its developments and anticipates the registration of its product HEMO2Life® which is an additive to organ preservation solutions to enhance, and improve organ quality and preservation duration and conditions in the transplantation field. As one the world’s leading Life Sciences hubs, Boston and Cambridge, has a most flourishing and attractive environment, and therefore is a natural choice for a biotechnology company like HEMARINA.


Dr. Franck Zal, Chief Executive Officer and Scientific Executive Officer
, HEMARINA commented: “The U.S. pharma and biotech markets tend to be early technology adopters, and Boston is an ideal location for Hemarina Inc. to benefit from this rich innovation ecosystem from a culture and networks perspectives. Furthermore, the new affiliate office is expected to facilitate the administrative and operational processes required for HEMARINA with its scientific and commercial partners in the United States including ongoing collaborations such as with the Naval Medical Research Center (NMRC) and Naval Medical Research Unit of San Antonio (NAMRU-SA).” The affiliate has been organized in collaboration with the law firm of Morse, Barnes-Brown & Pendleton, and ITRA Global The Stevens Group. Morse, Barnes-Brown & Pendleton will continue to act as legal counsel for Hemarina Inc. in its operations. The offices of Hemarina Inc. will be located in Ten Post Office Square, 8th Floor Boston, MA 02109.

About HEMARINA: HEMARINA is a biotechnology start-up based in Morlaix, France; developing innovative solutions for patients and healthcare industry based on its universal oxygen carriers portfolio and pipeline products. HEMARINA has four core business programs, all of which are patented breakthrough innovations: organ transplantation and tissue conservation, blood substitutes, infections and wound healing, and bio-production. HEMARINA’s core assets and know-how are based on marine molecules, and its corporate culture, policy and social responsibility are based on a focus on large unmet medical needs, a public health issues-solving mindset, excellence in science and processes, and nature conservation and environment friendly approaches and attitudes.
For more information about HEMARINA, please visit www.hemarina.com

About Morse, Barnes-Brown & Pendleton: Morse, Barnes-Brown & Pendleton focuses exclusively on the core legal services that businesses need to succeed. The firm is built on a unique business model that provides its clients with access to highly experienced counsel in the areas of corporate and corporate finance law; intellectual property; licensing and strategic alliances; employment and immigration; and tax planning and defense. While it enjoys a reputation for special competency in life sciences and other technology ventures, it represents clients in all industries and of all sizes – from startups to Fortune 1000 companies.
For more information about Morse, Barnes-Brown & Pendleton, please visit www.mbbp.com

About ITRA Global | The Stevens Group: The Stevens Group was founded in 1980 to provide commercial real estate services to corporate clients, assisting them in the leasing, acquisition and disposition of commercial real estate. The Stevens Group’s mission is to provide its clients with the most complete, unbiased real estate advice and the most efficient systems in business real estate, combining international reach and local knowledge to obtain the best possible space at the best possible terms.
For more information about ITRA Global The Stevens Group, please visit www.thestevensgrp.com/

Contacts:
For HEMARINA & Hemarina Inc: Phone: +33 298 880 360 E-mail: media@HEMARINA.com Website: www.hemarina.com Twitter: @HEMARINA Facebook: HemarinaBiotech
For MBBP: Phone: +1-781-697-2223 E-mail: pbarnes-brown@mbbp.com Website: www.mbbp.com
For Stevens Group: Phone: +1-617-886-9300 E-mail: dstevens@thestevensgrp.com Website: www.thestevensgrp.com

HEMARINA raises €6.3 Million in Series B Funding


This financing will help Hemarina bring to market its first product in the field of organ transplant, and will also strengthen its infrastructure as well as its R&D programs.

Morlaix, Finistère, France – July 10th, 2012 – HEMARINA, the most promising provider of universal oxygen carrier, today announced its €6.3 million in Series B funding. The syndicate was led by Inserm Transfert Initiative and includes historical investors such as Finistère Angels, Armor Angels, XMP and Arkéa Capital Investissement; and also a new entrant which is a family office represented and mandated by M. Maurice Lesaffre.

HEMARINA develops extracellular hemoglobin with a broad range of medical and industrial applications. Its pipeline is based on more than 20 years of research in marine biotechnology as well as through observation of marine biodiversity. Hemarina has four core business programs each of which is supported by patented breakthrough innovations: organs transplantation and tissues conservation; blood oxygen carriers; infections and wound healing; and bio-production. The Morlaixbased company is predicting to bring its first medical application product by end of 2013 in the field of kidney transplant.

This investment will help HEMARINA bring its first product to the market, (in the field of organ transplant), strengthen its organization and infrastructure, sustain its R&D programs, and finalize strategic alliances under discussion.

We are anticipating a fruitful and great future for HEMARINA,” said Franck Zal, CEO. “With this round of fundraising we are looking forward to putting strategy into action as well as broadening our perspectives; this new round of investment shows the trust of our new partners and board members and we are committed to bring HEMARINA within a leading position in its field.

“Inserm Transfert Initiative has been committed to supporting Hemarina since its seed financing. We are convinced that this innovative technology is one of the most appealing and promising oxygen carriers in development”, added Matthieu Coutet, Managing Partner, Inserm Transfert Initiative.

We have supported HEMARINA since its earliest stages and so it was without hesitation that we participated in this B-round financing, and we are convinced to be witnessing the birth of a biotechnology company of international stature”, said Patrick Franchet, first President of Finistère Angels and representative of all Business Angels inside HEMARINA Board.

I'm very excited to accompany Dr Franck Zal in this great entrepreneurial endeavor that will give me the opportunity to support a promising company and go thru its development, just as I started my own businesses in the past”, commented Maurice Lesaffre.

About HEMARINA

HEMARINA is a biotechnology start-up based in Morlaix, France; developing innovative solutions for patients and healthcare industry based on its universal oxygen carriers portfolio and pipeline products. HEMARINA core assets and know-how are based on marine molecules and its corporate culture, policy and social responsibility are based on high unmet medical needs focus, public health issues solving mindset, excellence in science and processes, nature conservation and environment friendly approaches and attitudes.

Lawyers:

For Hemarina: Priscilla Fiorucci -Chevalier Péricard Connesson & Associés.
For the Investors : Louis D’Urzo – Cabinet Orsay

ANR selects Hemarina’s HEMO2Perf® project

Morlaix, Brittany, Novembre 7th, 2011 - The French National Research Agency is to fund the HEMO2Perf® project, demonstrating once again the scientific and therapeutic interest in the oxygen carriers that Hemarina develops. This funding will pave the way to the clinical use of the Hemo2Life® solution for preserving kidney grafts.

Morlaix (France), 7 November 2011 — Hemarina, a French biotechnology firm specialized in the research and development of marine-derived oxygen carriers for therapeutic, industrial and research applications, announced that the French National Research Agency (ANR) selected the HEMO2Perf® project under the call for proposals for the ‘Biomedical Innovation through public-private Research Partnership (RPIB)’ program. The HEMO2Perf® project teams up Hemarina, the INSERM U927 research unit “Ischemia-reperfusion in kidney transplantation” at the Poitiers University Hospital, and the Health, Life, and Agricultural Sciences Infrastructures (IBiSA) facility ‘Surgery, Experimentation, Transplantation’ in Surgères.

“The HEMO2Perf® project involves the preclinical evaluation of HEMO2Life® for the storage of kidney transplants in preservation solutions and machine perfusion systems, explained Professor Thierry Hauet from the INSERM U927 research unit and scientific officer of the IBiSA ‘Surgery, Experimentation, Transplantation’ facility in Surgères. “The first proof of concept has already been obtained for HEMO2Life® in cold static storage. These results were published in September 2011 in The American Journal of Transplantation and show that presevation solutions supplemented with HEMO2Life® lead to better preservation and faster recovery of kidney function after transplantation (1). Machine perfusion can oxygenate the kidney during organ storage. Adding an oxygen carrier such as HEMO2Life® to a machine perfusion system may also enhance the preservation of ‘borderline’ kidney grafts in perfusion machines. This is what we seek to test during the HEMO2Perf® project.

The HEMO2Perf® project is to last three years and will receive € 700,000 in ANR funding. The work will be conducted on preclinical pig models at the ‘Surgery, Experimentation, Transplantation’ facility in Surgères.

Our goal is to significantly improve the quality of organ preservation, which should limit the side effects of preservation,” said Thierry Hauet. Better quality transplant organs should lead to better recovery of organ function post-transplantation and limit the ischemia-reperfusion injuries that are extremely detrimental for transplant patients and costly for the health-care system.

We are very pleased that HEMO2Perf® was selected by the ANR review committee, said Franck Zal, founder and director-general of Hemarina. “HEMO2Perf® aims to position Hemarina as the key biotechnology company in the field of graft preservation. No new progress has been made in this field for more than 20 years. The current solutions have now entered into the public domain and only contain water, salts and sometimes colloids, and do not offer optimal graft preservation. Graft preservation is nevertheless a key step in organ transplantation and can determine the success or the failure of a transplant — anti-rejection drugs cannot repair a damaged organ. Transplant organs have become more and more rare and are therefore all the more valuable. At Hemarina, we strive to offer optimal physiological conditions for organ graft preservation. Donors and their families, not to mention the organ recipients, deserve no less. Our collaboration with Thierry Hauet at the INSERM U927 research unit is very effective. His group, composed of leading experts in the field, is a major player in organ transplantation research and works to provide transplant surgeons with the best solution for their patients, said Franck Zal.

By selecting the HEMO2Perf® project, the ANR has once again recognized Hemarina for the quality of its work and scientific partnerships. Hemarina’s previous project, HEMORGAN on the use of an oxygen carrier derived from the extracellular hemoglobin of a marine organism to ensure better organ preservation before transplantation, had been selected under ANR calls for proposals ‘Emergence’ and ‘Biotechnology Research and Innovation’ in 2005 and 2007.HEMARINA plans to apply for a marketing authorization for HEMO2Life® in 2012. The application procedure will follow that required for ancillary therapeutic products (ATP).

 

(1) « Supplementation with a new therapeutic oxygen carrier reduces chronic fibrosis and organ dysfunction in kidney static preservation ». R Thuillier et al. American Journal of Transplantation 2011; 11(9): 1845-1860.

 

Ancillary therapeutic products (ATP) This category of therapeutics includes any product, except medical devices, that comes into contact with organs, tissues, cells or products of human or animal origin. Contact includes that which occurs during storage, preparation, transformation, packaging or transport before the actual human therapeutic use. ATPs primarily involve (tissue or organ) graft preservation solutions, media used for in vitro fertilization or media used for preparing cell therapy products. Marketing authorization is granted by the French Health Products Safety Agency (AFSSAPS) based on its review of the data provided by the manufacturer or importer on the quality, harmlessness and effectiveness in vitro of the product. The authorization is valid for a period of five years.

 

Biomedical Innovation through public-private Research Partnerships (RPIB) Launched in February 2011 by the ANR, the call for RPIB proposals selected 19 projects to fund from the 126 applications received. Designed to promote and facilitate technology transfer between the public and private sectors of biomedical sciences, the RPIB program requires that projects team up partners from academic research and private companies.

Project proposals were to target the discovery, development and optimization of therapeutic products, vaccines, or galenic formulations; diagnostic tools and products; or research tools or biomolecule production.

The ESOT Young Investigator Award

Morlaix, Brittany, September 15th, 2011 - HEMARINA, a young French biotechnology company that is developing breakthrough innovations from oxygen carriers of marine origin announces the distinction of the article recently appeared in the American Journal of Transplantation (Thuillier and al. Supplementation With has New Therapeutic Oxygen Carrier Reduces Chronic Fibrosis and Organ Dysfunction in Kidney Static Preservation, American Journal of transplantation. 2011; 11 (9) 1845-1860).

The "ESOT Young Investigator Award" was handed to Dr. Raphaël Thuillier (INSERM U927) during the 15th congress of the ESOT which was held at the beginning of September in Glasgow (Scotland). This prize rewards the quality of the work and the scientific contribution to transplantation. It is a new gratitude of the profit of the HEMO2life® solution developed by Hemarina as an additive for organ preservation solutions and the important stage which it represents in the field of the conservation of transplants.

American Journal of Transplantation

HEMARINA announces that a study on the use of HEMO2Life® has just been published in the American Journal of Transplantation, the leading journal in the field of transplantation
This paper establishes the scientific validity and benefit of hemoglobin M101, developed by HEMARINA as an additive for organ preservation solutions. This confirmation represents an important milestone for the preservation of grafts.

Co-authored by INSERM, INRA, CNRS, UPMC, and HEMARINA, this study published in the leading journal of organ transplantation demonstrates that the HEMO2life® solution developed by HEMARINA has been validated by the scientific and medical community.
Morlaix, France, August 31, 2011 – HEMARINA, a young French biotechnology company that is developing breakthrough innovations from oxygen carriers of marine origin for therapeutic and industrial use announces the publication of a study demonstrating the major benefits of HEMO2life® in comparison to the organ preservation solutions currently used in private hospitals (Thuillier et al. Supplementation With a New Therapeutic Oxygen Carrier Reduces Chronic Fibrosis and Organ Dysfunction in Kidney Static Preservation, American Journal of Transplantation. 2011; 11(9):1845-1860).
This study confirms the efficiency of the innovative technology developed by HEMARINA. The in vivo trials show that the addition of HEMO2life® to the most frequently used preservation solutions on the market leads to better preservation and faster recovery of kidney function after transplantation. Therefore, on the short term, the use of HEMO2life® promotes immediate organ function and, on the long term, it reduces inflammation and thus leads to better preservation of organ integrity.
These results demonstrate that the transplant performed with a kidney preserved in a HEMO2life®-supplemented solution has better prognosis for transplant success and for organ recovery post-transplantation. HEMO2life® maintains the transplant organ in better conditions by providing continuous oxygenation, according to the organ’s needs and without causing oxidative stress.
“HEMARINA is delighted to have finalized HEMO2life® so quickly. HEMO2life® is an innovative solution that protects grafts and grafts are a second chance for patients to live normally. Because transplant organs are becoming rarer, it is essential to preserve them in the best possible conditions and avoid the problem of delayed graft function, which can damage the organ,” declared Franck Zal, Ph.D., co-founder and General and Scientific Director of HEMARINA. "Since Hemo2life is a secondary therapeutic product, the marketing
authorization process is shorter than for drugs and we predict that this solution will be available for graft preservation in France as of 2012."
Given the current shortage of transplant organs, these positive results mark an important step in the field of transplantation. Not only should HEMO2life® improve the transplant success rate, but it also should enhance “borderline” organs and thus increase the number of grafts available for transplant.
Finally, by improving post-transplant kidney function, HEMO2life® should decrease the need for dialysis in transplant patients. Dialysis is an expensive medical routine and very costly for the health-care system.
This study was conducted in conjunction the CNRS UMR 7144 research unit directed by Professor François Lallier (CNRS and UPMC University Paris 6), the INSERM U927 research unit led by Professor Thierry Hauet in Poitiers, and the IBiSA “Surgery, Experimentation, Transplantation” facility at INRA (Domaine Expérimental du Magneraud).
About HEMARINA
Based in Morlaix, Brittany, France, HEMARINA is an innovative biotechnology R&D company. All its technology has been patented (licensed to UPMC-CNRS) and is based on over twenty years of fundamental research. HEMARINA was founded in March 2007 by researchers who discovered a family of extracellular hemoglobins found in marine organisms that satisfy all the requirements needed to develop a universal oxygen carrier. HEMARINA strives to build mutually beneficial collaborations with leading research laboratories and pharmaceutical, biotechnology, and veterinary companies.
For more information on HEMARINA, visit www.hemarina.com.

HEMARINA Signs Research Agreement to Study

HEMARINA Signs Research Agreement to Study the last generation of universal oxygen carrier, HEMOXYcarrier®
Morlaix, Finistère, France 28th February 2011 HEMARINA, a French Biotechnology company developing breakthrough innovation for therapeutical applications using marine oxygen carrier, today announced that it has recently entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center for the use of HEMOxycarrier®, the last generation of universal oxygen carrier. The CRADA, titled, Advancing Oxygen Therapeutic Agent development by evaluating the vasoactivity, oxygen carrying capacity, and effectiveness of HEMARINA-M101 (HEMOXYcarrier®) in a non clinical model as a pre hospital resuscitation fluid for traumatic brain injury, with or without hemorrhagic shock is a three-year study that will test the HEMOXYcarrier® on laboratory models.
This research responds to the identified medical need to improve pre-hospital aid of traumatic brain injury (TBI), which may be complicated by hemorrhagic shock (HS), by evaluation novel oxygen therapeutics that may reduce neurological damage in the immediate post-injury phase. This novel generation of oxygen therapeutic agent should be screened for potential use. Therefore, a screening survey is proposed to evaluate HEMOXYcarrier® for pre-hospital use in combat casualties with TBI/HS. The financial conditions were not being disclosed.
"The overall objective of this research agreement is the evaluation of the HEMOXYcarrier® product in the pre- hospital setting for casualties with polytrauma TBI/HS" said Dr. Franck ZAL, HEMARINA’s Chief Executive Office and Chief Scientific Officer. Dr. Franck ZAL also indicated that the preclinical studies already obtained by the company and by a research group of the University of California, San Diego on this product are very positive and do not possess the adverse effects demonstrated for the other generations of the Hemoglobin Oxygen Carrier (HBOC). Indeed, other HBOC were manufactured using chemically modified intracellular vertebrate hemoglobin (bovine and human) in order to work extracellularly, whereas HEMOXYcarrier® is no viscous and composed of giant extracellular hemoglobins, which was already selected by the evolution millions of years ago and work already free in the circulation of marine organisms, and do not provoke vasoconstriction after perfusion on animal models.
About HEMARINA
HEMARINA based in Morlaix, Finistère, France, is an innovative Research and Development company in biotechnology. All his technology is patented (licence UPMC-CNRS) and based on over twenty years of fundamental research. The founders of this company created in March 2007 have identified a family of extracellular hemoglobins coming from marine organisms that answer at all the specifications needed to make an universal oxygen carrier. The Company is focused on developing mutually beneficial agreements with leading research laboratories, pharmaceutical, biotechnology, and veterinary companies.
For more information about Hemarina, visit www.hemarina.com.


Corporate
Technology & Products
Intellectual Property
Investors News & Media

>> Company Overview
>> Managment Team
>> Board of Directors
>> Scientific and Ethics Board
>> Hemarina Label and Public Funding

>> Organ Preservation
>> Wound Healing
>> Hemoglobin Oxygen-Carrier
>> Cell Culture and  Bioproduction
>> Other Perspective


>> Portfolio
>> Literature References

 

>> News
>>
Hemarina Awards
>>
Press Releases
>>
Video Releases
>> 2013